SRC and glioblastoma: Taken together, these results suggest the capacity of the D1 peptide to inhibit IL-13-mediated cell signalling through FAK, Src, AKT and ERK1/2 in colorectal cancer and glioblastoma cell lines and the induction of MT1-MMP in glioblastoma cells.